Abs 1187 apremilast may have beneficial effects on cardiometabolic measures including reductions in HbA1c in severely obese patients and reductions in weight and dz activity improvements in PsO/ PsA outcomes across all BMI categories. #ACR22 @RheumNow https://t.co/fCdJxz2IDk https://t.co/mLnwKQs539
Links:
Obesity Burden and Effects of Apremilast on Changes in Cardiometabolic Paramete…
http://ow.ly/vESX50Lz2Wy
13-11-2022